Get the Stockscreener App
7.385
2.22%
-0.145
Abeona Therapeutics Inc stock is currently priced at $7.385, with a 24-hour trading volume of 109.19K.
It has seen a -2.22% decreased in the last 24 hours and a -2.74% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $7.74 pivot point. If it approaches the $7.30 support level, significant changes may occur.
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Abeona Therapeutics Inc (ABEO) Net Income 2024
ABEO net income (TTM) was -$54.19 million for the quarter ending December 31, 2023, a -36.51% decrease year-over-year.
Abeona Therapeutics Inc (ABEO) Cash Flow 2024
ABEO recorded a free cash flow (TTM) of -$37.34 million for the quarter ending December 31, 2023, a +14.38% increase year-over-year.
Abeona Therapeutics Inc (ABEO) Earnings per Share 2024
ABEO earnings per share (TTM) was -$2.58 for the quarter ending December 31, 2023, a +60.68% growth year-over-year.
Abeona Therapeutics Inc Stock (ABEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Alvino Mark | Director |
Jan 17 '24 |
Sale |
5.11 |
7,084 |
36,199 |
62,816 |
| Seshadri Vishwas | Chief Executive Officer |
Sep 27 '23 |
Buy |
4.07 |
20,000 |
81,400 |
521,731 |
| Charles Faith L. | Director |
Sep 27 '23 |
Sale |
4.91 |
8,330 |
40,924 |
70,773 |
| Alland Leila | Director |
Sep 27 '23 |
Sale |
3.90 |
7,246 |
28,270 |
71,857 |
| Alvino Mark | Director |
Sep 27 '23 |
Sale |
3.91 |
6,316 |
24,724 |
69,900 |
| Silverstein Christine Berni | Director |
Sep 27 '23 |
Sale |
3.91 |
6,330 |
24,721 |
87,884 |
| Amoroso Michael | Director |
Sep 27 '23 |
Sale |
3.91 |
5,508 |
21,542 |
108,957 |
| Amoroso Michael | Director |
Sep 20 '23 |
Sale |
3.90 |
327 |
1,275 |
114,465 |
| Vazzano Joseph Walter | Chief Financial Officer |
Sep 19 '23 |
Buy |
3.82 |
3,000 |
11,458 |
238,179 |
| O'Malley Brendan M. | SVP, General Counsel |
Sep 18 '23 |
Buy |
3.80 |
3,000 |
11,400 |
187,421 |
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
GlobeNewswire Inc.
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Benzinga
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
GlobeNewswire Inc.
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
COMPANY PROFILE
NameAbeona Therapeutics Inc
SectorHealthcare (1194)
IndustryBiotechnology (685)
Web
Phone646 813 4701
Employee90
Twitter
@abeonabio
SEC filings
Latest SEC Filings
Next earning date2024-05-09
Address1330 Avenue of the Americas, 33rd Floor, New York, NY, United States (10019)
1.63%
0.37%
Cap:
|
Volume (24h):